Nuwellis Q4 Revenue Up 4%, Gross Margin Expands; Secures $5M Financing, Announces Acquisition
NUWE is trading near its 52-week low of $1.195 (7.1% above the low) on light trading volume (0.1× avg).
Summary
Nuwellis, Inc. reported its fourth quarter 2025 financial results, showing a 4% year-over-year revenue increase to $2.4 million and a notable expansion in gross margin to 68.2% from 58.4% in the prior-year quarter. While the company posted a Q4 net loss of $2.4 million and a full-year net loss of $17.5 million on a 5% revenue decline, the Q4 operational improvements are a positive signal. This earnings release follows earlier reports of an expected $1.56 per share loss and an actual $1.50 per share loss, which was better than anticipated. Critically, the company also highlighted recent strategic moves including a $5.0 million private placement in January 2026 to bolster its capital position, the appointment of a new Chief Financial Officer, and the execution of a definitive agreement to acquire Rendiatech, expanding its cardiorenal portfolio. These developments are material for the small-cap medical technology firm, indicating efforts to strengthen its financial foundation and strategic growth. Traders will be watching for successful integration of the acquisition and sustained operational improvements.
At the time of this announcement, NUWE was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $1.20 to $56.28. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.